Similar articles

• NIH workshop tries to create consensus on HRT use.

  Randal J. Randal J. J Natl Cancer Inst. 2003 Jan 1;95(1):9-11. doi: 10.1093/jnci/95.1.9. J Natl Cancer Inst. 2003. PMID: 12509392 No abstract available.
• Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial.

  Pines A, Sturdee D. Pines A, et al. Ann Intern Med. 2010 Jul 6;153(1):61; author reply 61-2. doi: 10.7326/0003-4819-153-1-201007060-00020. Ann Intern Med. 2010. PMID: 20621912 No abstract available.
• Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial.

  Sullivan JL. Sullivan JL. Ann Intern Med. 2010 Jul 6;153(1):61; author reply 61-2. doi: 10.7326/0003-4819-153-1-201007060-00021. Ann Intern Med. 2010. PMID: 20621911 No abstract available.
• [Postmenopausal hormone replacement therapy and cardiovascular risk: role of conjugated equine estrogens and medroxyprogesterone acetate].

  Ortmann J, Traupe T, Vetter W, Barton M. Ortmann J, et al. Praxis (Bern 1994). 2004 May 19;93(21):904-14. doi: 10.1024/0369-8394.93.21.904. Praxis (Bern 1994). 2004. PMID: 15216975 Review. German.
• Do estrogen effects on blood vessels translate into clinically significant atheroprotection?

  Pradhan S, Sumpio BE. Pradhan S, et al. J Am Coll Surg. 2004 Mar;198(3):462-74. doi: 10.1016/j.jamcollsurg.2003.09.026. J Am Coll Surg. 2004. PMID: 14992749 Review. No abstract available.